Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032771 · ClinicalTrials.gov registry record · NA
Impact of M22 Synergistic Sequential Treatment (SST)
A NA study, sponsored by Lumenis Be.
- Completed
- Registry status
- NA
- Development phase
- 33
- Enrollment target
NCT02032771: Completed NA study, sponsored by Lumenis Be.
NCT02032771 is a NA study that has completed, run by Lumenis Be. The registered enrollment target is 33 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02032771, a NA study, has completed, sponsored by Lumenis Be.
- COMPLETED
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
Study Summary
Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation by at least 1 on the FES scale or ≥50% in category scale at 3 months follow-ups in at least 50% of the study population.
Primary Outcome
Skin improvement by Fitzpatrick Elastosis Scale (FES) or category scale at 3 months based on before/after photos
Interventions
- DEVICE M22 IPL and ResurFX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-02 |
| Phase | NA |
What the finished NCT02032771 record still lists
NCT02032771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which M22 IPL and ResurFX is the first listed.
NCT02032771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02032771 about?
NCT02032771 is a clinical study titled "Impact of M22 Synergistic Sequential Treatment (SST)". Up to 40 healthy subjects at 2 sites, age 30-65 year old with Fitzpatrick-Elastosis score of 3-6 and mild to moderate age/sun-related facial pigmentation that wish to improve their facial skin appearance. Hypothesis: The SST will improve the appearance of the wrinkles/elastosis and/or pigmentation ...
What is the current status of trial NCT02032771?
This trial is currently completed. It is a NA study. The enrollment target is 33 participants. The study started on 2014-01. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02032771?
The interventions under investigation include: M22 IPL and ResurFX (DEVICE).
Who is sponsoring clinical trial NCT02032771?
This trial is sponsored by Lumenis Be, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02032771's enrollment target sits among peer trials
33 1574th of 2000 higher than 423 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia